tiprankstipranks
Trending News
More News >
BioVaxys Technology (TSE:BIOV)
:BIOV

BioVaxys Technology (BIOV) AI Stock Analysis

Compare
19 Followers

Top Page

TS

BioVaxys Technology

(OTC:BIOV)

Rating:29Underperform
Price Target:
BioVaxys Technology faces severe financial challenges, with no revenue and reliance on external financing, which heavily impacts its overall score. Technical analysis indicates weak momentum and a bearish trend, while the negative valuation metrics highlight the risks involved. However, the company is taking steps towards financial management and exploring new market opportunities, which could improve its future prospects.

BioVaxys Technology (BIOV) vs. iShares MSCI Canada ETF (EWC)

BioVaxys Technology Business Overview & Revenue Model

Company DescriptionBioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
How the Company Makes MoneyBioVaxys Technology generates revenue primarily through the development and commercialization of its vaccine candidates. The company aims to monetize its proprietary haptenized vaccines through licensing agreements, partnerships with pharmaceutical companies, or direct sales upon approval. Significant factors contributing to its earnings include strategic collaborations with research institutions and potential government grants or funding for vaccine development. BioVaxys also explores opportunities for partnerships in the development and distribution of its immuno-diagnostic products.

BioVaxys Technology Financial Statement Overview

Summary
BioVaxys Technology demonstrates significant financial challenges, with no revenue generation and sustained losses affecting all financial verticals. The balance sheet reveals negative equity, and cash flows are heavily reliant on financing activities. These factors indicate high financial risk and potential sustainability issues in the biotechnology industry.
Income Statement
10
Very Negative
The company has consistently reported no revenue, resulting in negative EBIT and net income. The lack of revenue growth and profitability highlights significant challenges in the business model or market conditions.
Balance Sheet
15
Very Negative
The company's balance sheet shows negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio is not applicable due to negative equity, and the equity ratio is negative, signaling financial instability and potential solvency risks.
Cash Flow
20
Very Negative
The company exhibits negative operating and free cash flows, reflecting an inability to generate positive cash from operations. Financing cash flow is positive, suggesting reliance on external funding to support operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.00
EBITDA-3.63M-3.95M-7.69M0.00-6.42M-1.09M
Net Income-5.54M-3.95M-7.69M-11.73M-6.46M-1.17M
Balance Sheet
Total Assets1.28M1.30M113.48K865.56K8.50M10.46M
Cash, Cash Equivalents and Short-Term Investments157.41K211.81K977.00141.90K593.12K2.42M
Total Debt67.72K68.08K0.000.000.000.00
Total Liabilities3.02M3.22M3.49M1.64M326.86K900.09K
Stockholders Equity-1.74M-1.92M-3.37M-773.53K8.18M9.56M
Cash Flow
Free Cash Flow-2.76M-2.92M-1.05M-1.57M-5.29M-1.23M
Operating Cash Flow-2.76M-1.86M-1.05M-1.57M-5.29M-1.23M
Investing Cash Flow-1.06M-1.06M0.000.000.0061.36K
Financing Cash Flow3.01M3.13M917.10K1.11M3.44M3.35M

BioVaxys Technology Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.04
Price Trends
50DMA
0.04
Positive
100DMA
0.04
Negative
200DMA
0.05
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
55.53
Neutral
STOCH
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BIOV, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.53 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BIOV.

BioVaxys Technology Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
46
Neutral
C$192.85M-4.28-8.56%2.83%13.52%-1.74%
29
Underperform
$10.20M
48.63%
TSIOT
C$13.48M34.6222.65%
C$6.83M
TSTBP
$8.47M
$11.12M
41
Neutral
C$8.50M-247.04%2733.38%34.80%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:BIOV
BioVaxys Technology
0.04
-0.03
-42.86%
TSE:IOT
Innovotech
0.27
0.13
92.86%
TSE:COOL
Core One Labs
0.14
0.00
0.00%
TSE:TBP
Tetra Bio-Pharma
0.02
0.00
0.00%
BETRF
BetterLife Pharma
0.06
-0.03
-33.33%
TSE:GLOW
Glow LifeTech
0.05
0.02
66.67%

BioVaxys Technology Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
BioVaxys and SpayVac Expand License to Target Aquaculture Market
Positive
Apr 22, 2025

BioVaxys Technology Corp. and SpayVac for Wildlife, Inc. have expanded their license agreement to include commercial aquaculture, targeting the farm-raised fish market with their no-booster fertility-control vaccines. This expansion presents a significant commercial opportunity, particularly in the global market for farm-raised Atlantic salmon and rainbow trout, offering a scalable and cost-effective solution for reproductive control. SpayVac’s vaccines, which utilize a patented liposome-based delivery platform, have shown efficacy in multiple animal species and are advancing towards regulatory approval for use in feral horses and deer populations. The U.S. Bureau of Land Management is a potential customer for managing feral horse populations, which have significant ecological impacts due to their growing numbers.

Spark’s Take on TSE:BIOV Stock

According to Spark, TipRanks’ AI Analyst, TSE:BIOV is a Underperform.

BioVaxys Technology Corp. faces significant financial challenges with no revenue and negative earnings, heavily impacting its overall score. Technical indicators provide mixed signals, while recent corporate events suggest some improvement in financial management. However, the negative valuation metrics highlight the risks involved in the stock.

To see Spark’s full report on TSE:BIOV stock, click here.

Delistings and Listing ChangesPrivate Placements and FinancingBusiness Operations and StrategyRegulatory Filings and Compliance
BioVaxys Technology Corp. Revokes Cease Trade Order and Settles Debt
Positive
Apr 10, 2025

BioVaxys Technology Corp. announced the revocation of a management cease trade order by the British Columbia Securities Commission following the completion of its required financial filings. Additionally, the company has settled a debt of $60,000 by issuing 1,200,000 common shares, which are subject to a four-month statutory hold period. This development marks a positive step in BioVaxys’s operational transparency and financial management, potentially enhancing its credibility and stability in the biopharmaceutical industry.

Private Placements and FinancingBusiness Operations and Strategy
BioVaxys Technology Corp. Announces Debt Settlement to Optimize Financial Operations
Positive
Apr 1, 2025

BioVaxys Technology Corp. has announced a debt settlement agreement with THECCSGROUP, where it will issue 1,200,000 common shares to settle a $60,000 debt. This strategic move aims to preserve the company’s cash for working capital, reflecting a focus on financial stability and operational efficiency. The settlement is pending regulatory approvals and highlights BioVaxys’s commitment to maintaining its market position while managing its financial obligations.

Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
BioVaxys Technology Corp. Updates on Management Cease Trade Order Status
Neutral
Mar 18, 2025

BioVaxys Technology Corp. has announced a bi-weekly update regarding a management cease trade order (MCTO) due to delays in filing its audited annual financial statements. The company is working with its auditor to complete the filings by March 30, 2025, and assures that while the MCTO is in effect, public trading of its shares will continue, although trading by its CEO and CFO is restricted. This situation highlights the company’s commitment to resolving the issue while maintaining transparency with stakeholders.

Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
BioVaxys Technology Corp. Receives Management Cease Trade Order Amid Filing Delays
Negative
Mar 4, 2025

BioVaxys Technology Corp. has been granted a management cease trade order (MCTO) by the British Columbia Securities Commission due to a delay in filing its audited annual financial statements and related documents. The delay is attributed to the recent acquisition of intellectual property and clinical-stage assets from IMV Inc., which has extended the audit process. While the MCTO restricts trading by the company’s CEO and CFO, the general public can continue trading the company’s shares. The company is committed to complying with alternative information guidelines and expects to complete the required filings by March 30, 2025.

Private Placements and FinancingBusiness Operations and Strategy
BioVaxys Settles Debt and Closes Final Private Placement Tranche
Positive
Feb 19, 2025

BioVaxys Technology Corp. has announced a debt settlement agreement with consultants by issuing shares to preserve cash for working capital. Additionally, the company extended its private placement closing date and closed its final tranche, raising $100,000, which will also be used for working capital. These moves are aimed at strengthening the company’s financial position, potentially impacting its ability to continue developing its innovative therapies and maintain its industry standing.

M&A TransactionsFinancial DisclosuresRegulatory Filings and Compliance
BioVaxys Faces Potential Filing Delay Amid Recent Acquisitions
Neutral
Feb 14, 2025

BioVaxys Technology Corp. has announced a potential delay in filing its annual financial statements due to the complexities involved in auditing its recent acquisition of intellectual property and assets from IMV Inc. The company is proactively seeking a management cease trade order from the British Columbia Securities Commission to address any filing delays, which would prevent its management from trading shares but not affect other stakeholders. This situation highlights the company’s commitment to transparency and suggests that operational and strategic integrations, like the DPX platform, will continue unhindered by this temporary setback.

Private Placements and Financing
BioVaxys Extends Private Placement Closing Date to February 14, 2025
Positive
Feb 8, 2025

BioVaxys Technology Corp. has announced an extension to the closing date of its non-brokered private placement offering, originally set for February 7, 2025, and now extended to February 14, 2025. This extension aims to allow additional investors to engage in the final tranche, with proceeds intended for working capital. The announcement could enhance BioVaxys’ financial flexibility and operational capacity, potentially strengthening its market position and offering stakeholders a more robust platform for future developments.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 29, 2025